ProfileGDS5678 / 1428871_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 73% 72% 76% 74% 67% 72% 75% 73% 73% 72% 73% 75% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4195871
GSM967853U87-EV human glioblastoma xenograft - Control 24.6973873
GSM967854U87-EV human glioblastoma xenograft - Control 34.6453872
GSM967855U87-EV human glioblastoma xenograft - Control 45.2405676
GSM967856U87-EV human glioblastoma xenograft - Control 54.8459274
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1205867
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5875372
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8966175
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.722273
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7154473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6251172
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.718473
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9141975
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6824273